Regeneron Acquisition of Oxular Wipes Out Oxular Workforce
Jan 3, 2025 · 2024 was a tough year for the biopharma industry, with several companies including Bayer, Bristol Myers Squibb and Johnson & Johnson are cutting hundreds or even thousands of employees.. BioSpace will continue to be your source of news on job cuts and restructuring initiatives throughout 2025. Follow along as we keep you up to date on which companies are …
FDA Issues Warning Letters Against Online GLP-1 Sellers
Dec 18, 2024 · The letters come amid the Outsourcing Facilities Association’s ongoing lawsuit against the FDA over the regulator’s decision to end the shortage for tirzepatide. The FDA last week issued warning letters against a handful of companies flagging violations regarding the promotion and sale of ...
Molecular Glue Degraders at Inflection Point as Pharma Dives In
Dec 16, 2024 · Molecular glue degraders aren’t the only protein degradation option in the works. Another, called PROTACs (proteolysis-targeting chimeras), are bifunctional molecules with two distinct binding sites—one for a target protein and one for an E3 ubiquitin ligase—that also act as a molecular glue to target a protein for destruction.
Latest News & Press Releases - BioSpace
Jan 10, 2025 · Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from which have largely mirrored the dismal success rate in ALS overall.
Companies - BioSpace
Jan 9, 2025 · BioSpace’s annual Best Places to Work list demonstrates a company’s desirability in the recruitment marketplace. Each organization’s merits are considered with particular emphasis on culture, career growth and development opportunities, leadership and innovation.
AbbVie Continues Deal-Making Spree With $200M Nimble Buy
Dec 16, 2024 · AbbVie on Friday announced that it will purchase immunology specialist Nimble Therapeutics for $200 million upfront as the pharma lays the groundwork for a comeback following its disappointing schizophrenia stumble.. Aside from the upfront consideration, which still remains subject to “certain customary adjustments,” according to Friday’s announcement, financial …
Novo Adds Novel Approach to Cardiometabolic Pipeline With
Dec 18, 2024 · A titan in the cardiometabolic space with its diabetes and obesity GLP-1 semaglutide, Novo Nordisk continues to push the envelope, striking a deal Wednesday with Photys Therapeutics to explore a new class of molecule.
Parabilis Medicines™ – Formerly FogPharma - BioSpace
Oct 28, 2024 · BioSpace is the digital hub for life science news and jobs.We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.
Phase III Clinical Trials - BioSpace
Jan 7, 2025 · If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor indicated in combination with BCG for high-risk non-muscle invasive bladder cancer patients who had not previously undergone BCG treatment.
Analysis vs Beliefs, CEO Challenges, GLP-1 Investments
Dec 19, 2024 · In this episode of Denatured, BioSpace's Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh speculate on the impending Trump administration, discuss current challenges faced by CEOs and weigh investment in GLP-1s.